Stocks · 2 months ago
BioNTech Oncology Faces $1B Buyback Warning Before ASCO
Can BioNTech Oncology turn its huge cash pile into a real cancer breakthrough before investors lose patience?
BioNTech SE BNTX
Loading live quote…
$91.80
+1.29
(+0.35%)
Price Chart
About BioNTech SE
BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also develops oncology drugs under Phase III clinical trial, including Gotistobart for metastatic non-small cell lung cancer, Pumitamig for small cell lung cancer and advanced/metastatic triple-negative breast cancer, and Trastuzumab pamirtecan for metastatic breast cancer and epirubicin and cyclophosphamide; and drugs under Phase 2/3 clinical trial, such as BNT113 for human papillomavirus and head and neck squamous cell carcinoma, as…
Analyst Consensus
Consensus Rating
BUY
Analysts
20
covering this stock
Mean Target
$121.37
+32.2% vs current
Current Price
$91.80
+0.35% today
12-Month Price Target Range
LOW TARGET
$74.02
HIGH TARGET
$153.80
Range based on 20 Wall Street analysts covering BNTX.
Recent Analyst Actions — 6 unique firms, latest first
- Jul 8, 2026 Maintain Morgan Stanley Overweight ($126 → $119)
- May 27, 2026 Upgrade UBS Neutral → Buy (+$117 → $135)
- May 22, 2026 Init Bernstein Market Perform PT $96
- May 6, 2026 Maintain Canaccord Genuity Buy ($171 → $158)
- May 6, 2026 Maintain Wells Fargo Overweight ($150 → $140)
- Apr 27, 2026 Reiterate HC Wainwright & Co. Buy PT $130
Recent Quarters
| Quarter | Revenue | YoY | Net Income | EPS (dil.) | YoY | Gross Margin | Op. Margin |
|---|---|---|---|---|---|---|---|
| Q1 2026 Mar 2026 | $118.1M | -35.4% | $-531.9M | $-2.10 | -21.4% | 39.5% | -568.3% |
| Q4 2025 Dec 2025 | $907.4M | — | $-305.0M | $-1.25 | — | 63.3% | -30.9% |
| Q3 2025 Sep 2025 | $1.52B | — | $-28.7M | $-0.12 | — | 90.2% | 43.1% |
| Q2 2025 Jun 2025 | $260.8M | — | $-386.6M | $-1.60 | — | 70.7% | -183.5% |
| Q1 2025 Mar 2025 | $182.8M | — | $-415.8M | $-1.73 | — | 54.2% | -307.2% |
Data from Yahoo Finance. YoY compares the same quarter of the prior fiscal year.
Latest BNTX Coverage
Activity